| Autor: |
GRENELL, R. G., MENDELSON, J., McELROY, W. D. |
| Zdroj: |
Archives of Neurology and Psychiatry; March 1955, Vol. 73 Issue: 3 p347-351, 5p |
| Abstrakt: |
A constantly increasing number of clinical reports has been appearing in the literature concerned with the effectiveness of a new drug in the treatment of certain neuropsychiatric disorders. The drug, in this country, is called chlorpromazine. It has been referred to in France (where the first clinical studies were carried out) as Largactil, or 4560 R. P.1 (Largactil is also its name in Canada).Chemically, this compound is 3-chloro-10-(γ--dimethylaminopropyl) -2-phenothiazine hydrochloride. It has a number of interesting pharmacological properties, which recently have been described (publications of the Rhône-Poulenc Special Research Laboratories and the Smith, Kline & French Laboratories).The clinical reports * agree in large measure that chlorpromazine appears to be useful in "the management of anxiety, agitation and manic states in psychoneurotic and in psychotic patients." It has been beneficial in a variety of conditions presenting a picture of psychomotor excitement, and Winkelman3 has concluded that |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
